Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$474.00K$474.00Kderived−21.3% vs Q4 2023 Net Income-$756.00K-$756.00KderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$275,000−14.3% Operating Incomederived-$699,000N/M Operating Cash Flowderived-$593,000N/M Margins · derivedGross margin58.0%+4.7 pt vs Q4 2023
Operating margin-147.5%+22.6 pt vs Q4 2023
Net margin-159.5%+11.9 pt vs Q4 2023
ended Jul 31, 2024 · filed Oct 29, 2024 · 90 d after period end